Philip A Hipskind, Ph.D. earned his BS degree from Indiana University and his doctorate in organic chemistry (completing the total synthesis of sterepolide & merulidial) with Prof. Barry Trost at Stanford University in 1991 where he was both a Tamaki Foundation and an American Chemical Society Predoctoral Fellow. Dr. Hipskind directly joined Lilly Research Laboratories as a medicinal chemist that same year. While at Lilly, he created a robust discovery and development portfolio from target to clinical proof of concept spanning Oncology, Endocrinology, Neuroscience, and Infectious Disease across small molecule, therapeutic protein, and antibody modalities. In addition to 14 first human dose milestones (including inventor of 6 generically named entities lanepitant, tasisulam, tildacerfont, taladegib, adomeglivant, and crenigacestat), he contributed significantly to both R&D effectiveness through gene family lead generation and therapeutic area platform leadership.
Phil holds 43 issued US patents, has 9 additional pending, and has authored over 50 peer-reviewed publications. He was also a founding and voting member of the TB Drug Accelerator of the Bill and Melinda Gates Foundation and a member of the Scientific Advisory Committee for the TB Alliance. Dr. Hipskind was a long-time member of the Lilly Portfolio Management Team overseeing all pre-clinical and clinical phase assets for LRL.
In 2018 Dr. Hipskind founded Lgenia Inc. to focus on lead generation for neglected diseases that disproportionately affect people living in poverty. Currently his company of 14 employees is a full collaborating member organization of the Tuberculosis Drug Accelerator, Bill and Melinda Gates Foundation. He is also serving as chair, Research and Development Scientific Advisory Committee for the TB Alliance, a visiting Scholar at Purdue University and Texas A&M University, and an Adjunct Professor of Medicine at Indiana University School of Medicine.